| Prev Close | 21.15 |
| Day Low/High | 20.24 / 21.42 |
| 52 Wk Low/High | 20.12 / 58.72 |
ACADIA Pharmaceuticals Inc. (ACAD)
20.72
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 160.05B |
| Market Cap | 3.38B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
3 Housing Plays With Solid Earnings
These names are building a sound foundation for growth.
My Takeaways and Observations
"I never knew how easy the game of baseball was until I entered the broadcasting booth." -- Mickey Mantle While the markets were relatively flat there was a lot of subsurface action. The Alternative to the Bullish View. I might be right I might be...
3 Fearless Predictions for the Second Half
The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.
3 Fearless Predictions for the Second Half
The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.
Non-FANG Stocks May Finally Get Some Love
Tech meltdown provides an opportunity for rotation into undervalued sectors.
4 Undervalued Biotech Stocks
Two are turnaround stories, and two are oversold.
Keep Biotech Trigger Fingers Holstered
Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.
3 Post-Earnings Biotech Buys
These names are now undervalued, despite solid results and good fundamentals.
3 Post-Earnings Biotech Buys
These names are now undervalued, despite solid results and good fundamentals.
Biowreck!
I am not sure if this has broader consequences, but biotech (especially of a speculative -- kind) is spitting the bit, again today. I have already mentioned Allergan AGN (which I am buying now). Celgene CELG and Gilead Sciences GILD can't rally ei...
Takeaways and Observations
"She's a witch of trouble in electric blue, In her own mad mind she's in love with you. With you. Now what you gonna do? Strange brew, kill what's inside of you." -- Cream, Strange Brew Strange brew! You have probably forgotten October, 1987....
Added to Allergan on Weakness
Allergan , a day ahead of its earnings release, is down by over $4 on no apparent news, save a rotation out of biotech. (iShares Nasdaq Biotechnology is -3% or -$7 and we see individual equity declines in Celgene , Gilead , Acadia Pharmaceuticals , ...
Takeaways and Observations
"I understand that there's a certain comfort in crowds, as well as a distrust of the remnants of individual opinion. I suppose that's a function of the human condition, human spirit and human nature." -- Kass Diary, "You Gotta Be in It To Win It?" ...
Some Midday Observations
"Every little swallow, every chick-a-dee Every little bird in the tall oak tree The wise old owl, the big black crow Flappin' their wings signin' "go bird, go" Rockin' robin, (tweet-tweet-tweet) Rock-rock-rockin' robin' (tweet-tweedilly-tweet) Go ro...
The Good, the Bad and the Ugly (Mid-Afternoon Edition)
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I have to prepare for my Tulane trip. So let's move to the abbreviated Monarc...
Takeaways and Observations (Early Edition)
'Til April in Paris, chestnuts in blossom Holiday tables under the trees April in Paris, this is a feeling That no one can ever reprise - April in Paris, Vernon Duke and Yip Harburg - (rare video with Ella Fitzgerald!) The market gapped higher and ...
2 Biotech Pullback Targets
Acadia and Neurocrine both have catalysts for growth; buy any weakness.
I'm Big on Housing Entering Quarter No. 2
Home builders make up the second-largest allocation in my portfolio, behind biotech.
What Poker Taught Me About Investing
I've learned that emotions have little use at a poker table; they don't in the stock market, either.
What Poker Taught Me About Investing
I've learned that emotions have little use at a poker table; they don't in the stock market, either.
Takeaways And Observations
For the first time in six years the DJIA fell for the eighth consecutive day. That said the Nasdaq has risen in ten of the last thirteen trading sessions as Donald Trump may be making volatility and uncertainty great again. (For that divergence and ...
Takeaways & Observations
Risk happens fast. Most don't short and shouldn't short -- it's a game that requires volumes of risk control. However, I would continue to maintain well above-average cash positions. Today was not a benign event, in my view. Nor was it likely a ...
4 Smaller Biotech Names Worth Researching
Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.
Your Burning Biotech Questions Answered
We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.
Your Burning Biotech Questions Answered
We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.
Biotech Buoyed by Deal Talk
M&A activity is in a serious upswing, and here are some names to watch.
Welcome to the Small-Cap Biotech Mailbag!
We answer recent reader questions about three of the biotech stocks we regularly cover.
The Next Target in Biotech Land
The Actelion buyout opens the way for other deals.
The Next Target in Biotech Land
The Actelion buyout opens the way for other deals.
My Takeaways and Observations
The market pushed back presumably after it digested the inaugural speech and absorbed the marches around the world. I don't believe the new president will be market and economy friendly. The reflation trade is in question today. And I remain b...
